Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors

Rheumatology (United Kingdom)

Volumn 53, Issue 8, 2014, Pages 1477-1481

  Kim, You Jae ^a   Kim, Yong Gil ^a   Shim, Tae Sun ^a   Koo, Bon San ^a   Hong, Seokchan ^a   Lee, Chang Keun ^a   Yoo, Bin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Inhibitor; Mycobacterium tuberculosis; Rheumatic disease; Safety; Tuberculosis; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION;

INHIBITOR; MYCOBACTERIUM TUBERCULOSIS; RHEUMATIC DISEASE; SAFETY; TUBERCULOSIS; TUMOUR NECROSIS FACTOR;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETREATMENT; RETROSPECTIVE STUDIES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904874694     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu041     Document Type: Article

References (21)

1. Walls RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-11.
2. Bekker LG, Freeman S, Murray PJ et al. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001;166:6728-34.
3. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
4. Solovic I, Sester M, Gomez-Reino JJ et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
5. Mariette X, Salmon D, Group R. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.
6. Kavanagh PM, Gilmartin JJ, O'Donnell J et al. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J 2008;101:6-7.
7. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
8. Costamagna P, Furst K, Tully K et al. Tuberculosis associated with blocking agents against tumor necrosis factoralpha-California, 2002-2003. JAMA 2004;292:1676-8.
9. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
11. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335:1078-80.
12. Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
13. Jung YJ, Lyu J, Yoo B et al. Combined use of a TST and the T-SPOT-TB assay for latent tuberculosis infection diagnosis before anti-TNF-alpha treatment. Int J Tuberc Lung Dis 2012;16:1300-6.
14. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculsosis. 1st edn. Cheongwon, Korea: Korea Centers for Disease Control and Prevention, 2011.
15. Denis B, Lefort A, Flipo RM et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe reinitiation of TNF-alpha blockers after appropriate antituberculous treatment. Clin Microbiol Infect 2008;14:183-6.
16. Blackmore TK, Manning L, Taylor WJ et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008;47:E83-5.
17. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009;48:1429-32.
18. Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
19. Korean National Tuberculosis Association. Trend of case notification rate per 100,000 by year, 2004-2011. Seoul: Korean National Tuberculosis Association, 2011. http://www.knta.or.kr (1 February 2013, date last accessed).
20. Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
21. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.